Peptides for Myostatin Inhibition
Overview
2 research peptides are currently studied for myostatin inhibition. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Trevogrumab — Phase II-III clinical trials ongoing
Evidence Rating: C Category: Muscle Growth / Monoclonal Antibody
Trevogrumab (REGN1033) is a fully human monoclonal antibody that specifically binds and neutralizes myostatin (GDF-8), developed by Regeneron Pharmaceuticals. It is being studied in combination with other agents for sarcopenia (age-related muscle loss) and muscle wasting conditions. Trevogrumab repr...
Key claims: Increases lean muscle mass; Treats inclusion body myositis.
Myostatin Propeptide — Preclinical
Evidence Rating: D Category: Muscle Growth
Myostatin propeptide is the N-terminal prodomain of myostatin (GDF-8) that acts as an endogenous inhibitor of mature myostatin signaling. When myostatin is cleaved from its precursor protein, the propeptide remains non-covalently associated with the mature domain, keeping it in a latent, inactive co...
Key claims: Increases muscle mass by inhibiting myostatin; Natural myostatin inhibition causes dramatic muscle growth.